Granulocyte-colony-stimulating factor after allogeneic and autologous bone marrow transplantation in children.
We evaluated the use of granulocyte CSF (G-CSF) after both allogeneic BMT (allo-BMT) and autologous BMT (ABMT) in children. After allo-BMT, G-CSF was used in 15 children who were compared with 20 historical controls. The ABMT patients were two sequential groups: the G-CSF group of 13 children and 11 historical controls. The patients were conditioned with different high-dose chemotherapy regimens with or without total body irradiation. G-CSF was administered at 5 micrograms/kg/day s.c. and was continued until an absolute neutrophil count (ANC) of 1,000 x 10(6)/l was reached. Following allo-BMT, G-CSF accelerated myeloid engraftment with a difference of 5 days at the ANC level of 500 x 10(6)/l (P<0.02) and 9 days at 1,000 x 10(6)/l (P<0.001). In the ABMT patients, G-CSF also accelerated myeloid engraftment. The difference between the G-CSF group and the control group was 6 days at ANC 200 (P<0.05), 11 days at ANC 500 (P<0.02) and 17 days at ANC 1,000 (P<0.005). In the ABMT patients, benefit by G-CSF was also observed in a smaller number of days with fever and days on antibiotics. We conclude that G-CSG significantly accelerated myeloid engraftment, after both allogeneic and autologous BMT in children, and also decreased the duration of febrile illness in the ABMT patients.
Saarinen
U M
UM
Children's Hospital, University of Helsinki, Finland.
Hovi
L
L
Juvonen
E
E
Riikonen
P
P
Möttönen
M
M
Mäkipernaa
A
A
D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001424:Bacterial Infections / Q000517:prevention & control; D001792:Blood Platelets / Q000473:pathology; D001853:Bone Marrow / Q000187:drug effects; D016465:Bone Marrow Purging; D016026:Bone Marrow Transplantation / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D005260:Female; D005334:Fever / Q000517:prevention & control; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007279:Injections, Subcutaneous; D007958:Leukocyte Count; D008297:Male; D009504:Neutrophils / Q000187:drug effects / Q000473:pathology; D010865:Pilot Projects; D013997:Time Factors; D014916:Whole-Body Irradiation
D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D016179:Granulocyte Colony-Stimulating Factor